7,568.92

+27.52

+0.36%

51,786.72

-197.26

-0.38%

25,372.01

+207.65

+0.83%

2,812.45

+6.57

+0.23%

4.9520

+0.0580

+1.19%

20.83

-0.32

-1.51%

3,939.30

-30.30

-0.76%

77,801.08

+1,098.33

+1.43%

Crude Oil Dec 26

96.84

+0.38

+0.39%

US Private Equity

10,836.30

-14.33

-0.13%

LSE - Delayed Quote GBp

Shield Therapeutics plc (STX.L)

3.0500 -2.4500 (-44.55%)

At close: 5:10:53 PM GMT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Shield Therapeutics loses profitability target as Medicaid pressures offset prescription growth

Proactive 11h ago

STX.L
-44.55%
STX

SHIEF
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

Proactive 2mo ago

STX.L
-44.55%
VTRS

SHIEF
Shield Therapeutics jumps 11% as losses narrow and profitability target held

Proactive 2mo ago

STX.L
-44.55%
STX

SHIEF
Shield Therapeutics plc's (LON:STX) Path To Profitability

Simply Wall St. 5mo ago

STX.L
-44.55%
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh

Proactive 6mo ago

STX.L
-44.55%
Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty

PR Newswire 3mo ago

6576.TWO

STX.L
-44.55%
VERU
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel

Insider Monkey 6mo ago

PROK

STX.L
-44.55%

Performance Overview

Return	STX.L	FTSE 100 (^FTSE)
YTD	-69.04%	+7.12%
1-Year	-56.74%	+9.66%
3-Year	-51.59%	+43.42%

Mobilize your Website

View Site in Mobile | Classic

Share by: